DTILHIGH SIGNALRISK10-K

DTIL experienced a dramatic financial deterioration with net income swinging from $7.2M profit to -$45.7M loss while revenue dropped 50%, coupled with significant new risk factor language around clinical trial delays and regulatory approval challenges.

The company appears to be transitioning from a profitable phase to heavy investment/development spending, with substantially increased operational losses despite maintaining a strong cash position. The addition of multiple specific risk factors around clinical trial timelines, regulatory submissions, and patient enrollment suggests heightened uncertainty around their gene editing pipeline development and commercialization prospects.

Comparing 2026-03-12 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

DTIL's financials show a stark transformation from profitability to significant losses, with net income declining 738% to -$45.7M and revenue falling 50% to $34.3M, indicating either completion of major revenue-generating contracts or strategic pivot toward R&D investment. Despite operational challenges, the balance sheet strengthened considerably with cash increasing 29% to $110.8M and stockholders' equity growing 64% to $92.2M, while total debt increased dramatically by 797% to $22.2M, suggesting recent financing activities to fund the expanded clinical development program. The overall picture indicates a well-capitalized biotech company investing heavily in clinical trials but facing substantial near-term cash burn.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+796.8%
$2.5M$22.2M

Debt increased 796.8% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
-738%
$7.2M-$45.7M

Net income declined 738% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-99.3%
-$26.2M-$52.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Stockholders Equity
Balance Sheet
+63.6%
$56.4M$92.2M

Equity base grew 63.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
-50.1%
$68.7M$34.3M

Revenue declined 50.1% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
-40.5%
$15.0M$8.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+29%
$85.9M$110.8M

Cash grew 29% — improving liquidity position supports investment and shareholder returns.

Current Assets
Balance Sheet
+25%
$95.0M$118.7M

Current assets grew 25% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
-22.3%
$80.0M$62.2M

Liabilities reduced 22.3% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
-20.1%
$2.2M$1.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-26
ADDED
If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed.
We may not be able to submit INDs to the FDA or CTAs to comparable foreign authorities to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or comparable foreign authorities may not permit us to proceed.
Any delays or difficulties in our or our collaborators ability to enroll patients in clinical trials could delay or prevent receipt of regulatory approvals.
Results of preclinical studies and early clinical trials of product candidates may not be predictive of results of later studies or trials.
Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval.
+7 more — sign up free →
REMOVED
5 RISK FACTOR SUMMARY Our business is subject to numerous risks and uncertainties, including those described in Part I.
ARCUS is the only gene editor derived purely from a protein, called a homing endonuclease, that evolved in nature to safely edit a genome and add function.
There are several genome editing technologies, including ARCUS, zinc-finger nucleases ( ZFNs ), TAL-effector nucleases ( TALENs ), clustered regularly interspaced short palindromic repeats associated protein-9 nuclease ( CRISPR/Cas9 ), base editors and prime editors.
ARCUS can use different delivery vehicles including lipid nanoparticles ( LNP ) for the liver and adeno-associated viruses ( AAV ), which have 8 limited carrying capacity, to target diverse tissue types as ARCUS is very small relative to other genome editing endonucleases.
Because of its small size, ARCUS is also uniquely able to include an insertion DNA template in the same AAV, which allows targeting in vivo gene insertion in various tissues.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →